Yosemite’s $350M fund aims to rewrite cancer drug pipeline with AI
Reed Jobs says Yosemite’s second fund closed at $350 million, earmarked for building biotech startups that turn academic breakthroughs into cancer cures. The firm now has 17 staff, leverages AI for drug discovery and clinical trials, and splits capital—about a third into companies it creates itself. Blockbuster patent cliffs and AI progress are expanding the opportunity.